The objectives for 2021 are
- 4 additional products submitted for FDA review
- 2 product launches
Pimples were submitted on the 15th of April. The total sales there are US$206M. To meet the target, there should be 3 more submissions in the next 5 months. And 2 actual launches with revenues. Fungus is over $200M as well.
Then, for 2022,
•
Objective to be cash flow positive by end of 2022• Ongoing screening and initiation of new products in development
• 2 additional products submitted for FDA review
There are 10 generics in development (is that 9 now that pimples are submitted?). Presumably, a mix from the following:
- 53 identified topical drugs each >100M in sales
- 94 identified topical drugs each $10 - $100M in sales
I think once the company is cash flow positive, things change, since it becomes self-sustaining, and, at a constant pace of development, additional revenues are profit. End of 2022 is far away, so maybe that's why the market isn't thrilled by recent announcements. I would imagine concrete steps towards that profitability goal - ie the product launches - should get some response. I don't know though. Doesn't necessarily matter. If the profitability objective is reached by end of 2022, presumably either research is ramped up, or profits rise with additional products coming online. I'll take either. Assuming all of that pans out.
(20min delay)